BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosiswith AI-powered ER Status Prediction
BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia – (December 10, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in liquid biopsy tests for early […]
BioMark Expands its Liquid Biopsy Platform with two Groundbreaking Publications in Breast Cancer Detection
BioMark Expands its Liquid Biopsy Platform with two Groundbreaking Publications in Breast Cancer Detection BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia – (November 5, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced significant […]
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN BioMark’s Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia – (September 24, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, […]
BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection
BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia – (September 10, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for […]
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment Conference In New York
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment conference in New York Vancouver, British Columbia – (August 26, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that Chief Executive Officer […]
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY The new patent granted by the USPTO strengthens and expands BioMark’s global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia – (July 31, 2024) – BioMark Diagnostics Inc., (“BioMark” or the “Company”) […]
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research AT 2024 GPEN Conference
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia – (July 15, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long […]
A Day To Honour Dr. Daniel Sitar: Fellowship of the Society of Pharmacology and Therapeutics
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and Therapeutics Daniel Sitar BScPharm, MSc, PhD, FGSA,FCP, Professor Emeritus, Rady Faculty of Health Sciences – College of Medicine (Departments of Internal Medicine, Pharmacology and Therapeutics, Pediatrics and Child Health), College of Pharmacy, and Centre on Aging, University ofManitoba. Dr. Sitar […]
BIOMARK Announces Warrant Extension and Granting of Options
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Company intends to amend […]
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]
